A number can be both a beginning and a trap. In a completed early study of Electra Therapeutics’ experimental antibody, 11 of 12 frontline patients with malignancy-associated hemophagocytic lymphohistiocytosis were alive at day 60. For a condition that can turn an immune response into a medical emergency, that is the kind of figure that gets noticed. It is also a figure with a denominator small enough to fit around a dinner table.
Electra’s next job is to find out whether the result survives a much larger test. In September 2026, the South San Francisco company completed a $350 million initial public offering. Its shares began trading as ETRA on Nasdaq. The money gives Electra more room to run a global pivotal trial of its lead antibody, ipsoprubart, formerly ELA026. It does not settle the science.
- Electra designs antibodies to remove activated immune cells that help drive disease.
- Its lead program is in a global Phase 2/3 study for secondary HLH, a dangerous inflammatory syndrome.
- A second antibody, ELA822, entered a Phase 1 trial in September 2026.
- The company has no approved medicines or product revenue; its $350 million IPO funds the next tests.
When defense becomes damage
Secondary HLH, or sHLH, is a rare syndrome in which the immune system becomes dangerously overactive. Cancer, infection, autoimmune disease, and even immunotherapy can set it off. Fever and inflammation are only the opening act; patients can develop organ failure. The malignancy-associated form is particularly hard to treat because clinicians must address both the runaway immune response and the cancer that helped trigger it.
The established toolbox includes corticosteroids, etoposide-based regimens, and other immune-directed treatments. These can help, but outcomes remain poor, especially in malignancy-associated cases. That gap is Electra’s opening. Its hypothesis is unusually literal: identify the immune cells involved in the spiral, then remove them.
Electra calls its target family SIRP, short for signal regulatory proteins. These receptors appear on particular immune-cell populations and can be more abundant when the cells are activated. Ipsoprubart is a monoclonal antibody aimed at SIRPα, SIRPβ1, and SIRPγ. The company’s proposition is that this pattern provides a handle on pathological T cells and myeloid cells while preserving more of ordinary immune function. That selectivity is a design goal, not an established clinical outcome.
Frontline malignancy-associated HLH patients alive at day 60 in Electra’s completed Phase 1b analysis. All 12 had responded by week four.
Single-arm subgroup; company-reported 2024 dataThe denominator has a biography
The Phase 1b study was open label and had no randomized control arm. Electra reported a 100% response rate by week four in the 12-person frontline malignancy-associated subgroup, hospital discharge for 11 of 11 evaluable patients, and 92% survival at day 60. Those results justified a closer look. They cannot, by themselves, prove that the antibody caused the difference from historical outcomes; small studies are vulnerable to who gets enrolled, how illness is measured, and when treatment starts.
The pivotal SURPASS trial is Electra’s answer. It is a global, open-label Phase 2/3 study at sites in the United States and Europe, with an external control group. Its primary endpoint is eight-week survival in treatment-naïve patients with lymphoma-associated HLH. The study also follows safety, other measures of efficacy, and how the drug behaves in the body. It includes adult and pediatric patients under specified criteria. This is a demanding design for a rare, fast-moving illness, where a patient’s clock rarely waits for a clean experiment.
“Many approaches to T cell-driven diseases broadly suppress or deplete immune cells, which can limit their use in chronic settings.”Kim-Hien Dao, Electra chief medical officer, September 2026
The US Food and Drug Administration gave ELA026 Breakthrough Therapy designation, and the European Medicines Agency admitted it to its PRIME program in 2025. Both decisions offer more intensive regulatory engagement. Neither is an approval. The company still has to demonstrate that its drug works and can be used safely in the patients it hopes to reach.
One target family, two different gambles
Electra began inside Star Therapeutics in October 2018. Co-founder Adam Rosenthal was its first chief executive; by 2022 he was describing the journey from an idea to the clinic in less than three years. The company separated from Star in June 2023. Kathy Dong, who had helped build Electra within Star, became CEO that October. Her background includes drug launches at Gilead and commercial development roles, experience that becomes useful when a research company must plan for more than a promising graph.
Ipsoprubart is also being tested in a Phase 1 study for relapsed or refractory T-cell and natural-killer-cell malignancies. Electra dosed the first patient in May 2026, extending the same antibody into cancer. It is an expansion of the hypothesis, not evidence that the sHLH result transfers to tumors.
Then there is ELA822. Where ipsoprubart binds three SIRP family members, this second antibody is designed to bind SIRPγ specifically. The idea is to deplete activated, disease-driving T cells while sparing naïve and regulatory T cells. In September 2026 Electra started a randomized, placebo-controlled Phase 1 trial in healthy volunteers to examine safety and drug behavior. The split between a broad emergency program and a narrower chronic-disease candidate is the most revealing thing about its pipeline: the company is trying to turn one biological insight into different degrees of precision.
The invoice arrives before the medicine
This is a drug developer, not a clinic, a research service, or a pharmacy. Its future customers, if regulators approve its candidates, would be the hospitals and clinicians treating eligible patients. Today its immediate relationships are with trial participants, investigators, clinical sites, regulators, and investors. There is no approved Electra medicine to buy.
The financial sequence tells the story more plainly than any pitch deck. Electra announced an $84 million Series B in 2022 and a $183 million Series C in 2025, the latter co-led by Nextech and EQT Life Sciences. Its September 2026 IPO added $350 million in gross proceeds. According to its SEC prospectus, Electra generated no revenue and recorded a $62 million net loss in 2025, including $50.4 million in research and development expense. The $2.8 million annual-revenue estimate circulating in some company databases is at odds with the filing.
What changed the company’s course was evidence, then scale. A small clinical signal pushed ipsoprubart toward a registrational study. That study, in turn, pushed Electra into larger financing and public-company scrutiny. It is a sequence other drug developers can learn from: choose a disease where the biological target and a meaningful outcome connect, measure early signals honestly, then design the next trial to challenge the signal. It is no shortcut. If the patient group cannot be identified quickly, if historical controls are unreliable, or if selective depletion fails to improve survival without unacceptable harm, the logic stops working.
The public-market debut makes for a tidy date on a timeline. The untidy part begins afterward. Electra has to show that a result from 12 patients can survive contact with the world beyond those 12. For anyone who has watched an immune fire outrun a treatment plan, that is the question worth following.